Increased risk persists for up to six months postinfection for pediatric patients aged 0 to 18 years
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
Please see our Editorial and Fact-Checking Policy for more detail.
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Oct. 11, 2022 (HealthDay News) — Risk for a new diagnosis of type 1 diabetes (T1D) may persist for up to six months following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children, according to a research letter published online Sept. 23 in JAMA Network Open.
Ellen K. Kendall, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues used deidentified electronic health records from the TriNetX Analytics Platform to identify 314,917 patients aged 18 years or younger with SARS-CoV-2 infection between March 2020 and December 2021 and 776,577 propensity-matched patients without SARS-CoV-2 infection but with a non-SARS-CoV-2 respiratory infection during the same time period.
The researchers found that at one, three, and six months after infection, the risk for a diagnosis of T1D was greater among those who had experienced SARS-CoV-2 infection than among those who had experienced non-SARS-CoV-2 respiratory infection (one month: hazard ratio [HR], 1.96; three months: HR, 2.10; six months: HR, 1.83). Results were similar for patients aged 0 to 9 years and 10 to 18 years. When examining other pediatric control cohorts at six months, an increased risk for T1D persisted among children infected with SARS-CoV-2 (visits for fractures: HR, 2.09; well-child visits: HR, 2.10).
"The increased risk of new-onset T1D after COVID-19 adds an important consideration for risk-benefit discussions for prevention and treatment of SARS-CoV-2 infection in pediatric populations," the authors write.
Abstract/Full Text
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at solutions@healthday.com with any questions.
Physician’s Briefing Staff
Published on October 11, 2022
Copyright © 2020 HealthDay.
All rights reserved.
This website is certified by Health On the Net Foundation. Click to verify.
